Rubius Therapeutics to Present Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers at the American Association of Cancer Research Annual Meeting

• NASDAQ: $RUBY
• Notified: $6.00
• 08:01 EDT